Home About Us Industry Report Store Resources Contact us

Hormone Replacement Therapy Drug Market To Reach USD 28905 Million By Year 2032

Hormone Replacement Therapy Drug Market Size Was Valued at USD 15950 Million in 2023 and is Projected to Reach USD 28905 Million by 2032, Growing at a CAGR of 6.11% From 2024-2032.

Swati Kalagate
Pristine Intelligence LLP

According to a new report published by Pristine Intelligence LLP, titled, “Hormone Replacement Therapy Drug Market by Therapy, Indication, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2024–2032,” the Global Hormone Replacement Therapy Drug market size was valued at USD 15950 Million in 2023, and is projected to reach USD 28905 Million by 2032, registering a CAGR of 6.11% from 2024 to 2032. Hormone Replacement Therapy drugs consist of female hormones that take the place of hormones produced by the body before menopause. The types of hormones, administration methods, and dosage levels vary among hormone replacement therapy medications.

Hormone replacement therapy (HRT) improves quality of life by helping to control menopausal symptoms such as hot flashes, mood swings, and vaginal dryness. Estrogen in hormone replacement therapy helps to keep bone density healthy and improves heart health, lowering the risk of cardiovascular disease. Hormone replacement therapy is necessary for transgender individuals in gender-affirming care to match physical characteristics with gender identity using hormonal supplements.

The demand for Hormone Replacement Therapy (HRT) drugs has risen due to menopause, medical conditions, transgender transitioning, age-related changes, and improved healthcare. Hormone Replacement Therapy (HRT) helps both men and women by balancing hormone levels and relieving issues such as hot flashes, tiredness, and decreased sex drive. It also helps with gender-affirming treatments by causing wanted secondary sexual characteristics.

HRT medications have been linked to numerous health dangers like heart problems, breast cancer, and blood clotting disorders. Individuals with underlying heart conditions have increased concerns about the safety of these drugs. Moreover, estrogen-containing HRT medications can raise the chances of endometrial cancer in women who have not had a hysterectomy, with typical side effects including headaches and mood alterations.

The latest HRT drug forms offer accurate dosing, improved effectiveness, reduced side effects, and easy administration. Bioidentical hormones provide personalized therapy using hormones that are identical. Innovative delivery methods enhance patient satisfaction and compliance. HRT is being investigated for conditions other than menopause, such as hormone deficiencies, sexual health problems, and endocrine disorders. Research has revealed fresh insights on the combination of hormones, targets for therapy, and methods of treatment, which could broaden the market and improve options for patients.

Global Hormone Replacement Therapy Drug Market, Segmentation

The Hormone Replacement Therapy Drug market is segmented based on Therapy, Indication, Route of Administration, Distribution Channel, and region.


Menopause is a prevalent natural occurrence that impacts women globally as they get older, leading to a reduction in hormone levels and issues such as hot flashes and changes in mood. HRT drugs are in high demand due to the popularity of hormone replacement therapy for managing these symptoms.

Menopausal symptoms may endure for an extended time, requiring hormone replacement therapy drugs to manage the symptoms. Various types of hormone replacement therapy (HRT) administration, including patches and gels, enhance adherence to treatment and satisfaction among patients.

Route of Administration:

Taking HRT medication orally requires ingesting a tablet or capsule so that it can be absorbed through the digestive system. This pathway provides an easy and direct way to administer a range of HRT options in varying amounts and mixtures.

Oral hormone replacement therapy is economical and readily available due to the pharmaceutical industry's investments in improved formulations. Novel drugs such as SERMs and estrogen from plants provide better efficacy and safety for patients.


The market for hormone replacement treatments in North America is being fueled by the aging population. There is a high prevalence of hormonal imbalances and menopause symptoms in the elderly population, resulting in an increased need for these treatments. Research, education, and advocacy efforts in the region have led to a rise in awareness and acceptance of hormone replacement therapies. Advancements in drug delivery technology, such as patches and implants, have also played a role in the market's expansion, fueled by the region's significant healthcare spending.

Some of The Active Market Players Are-

    • Eli Lilly and Company (USA)
    • Bayer AG (Germany)
    • Noven Pharmaceuticals, Inc. (USA)
    • Pfizer Inc. (USA)
    • Merck & Co., Inc (USA)
    • Glenmark (India)
    • Novo Nordisk A/S (Denmark)
    • ASCEND Therapeutics US, LLC. (USA)
    • AbbVie, Inc. (USA)
    • Abbott Laboratories (USA)
    • Genentech Inc. (USA)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Novartis AG (Switzerland)
    • Theramex (UK)
    • Sun Pharmaceutical Industries Ltd. (India), and Other Active Players.

Key Industry Developments

    • February 2024: Knight Therapeutics Inc., a Pan-American specialty pharmaceutical company, announced the launch of BIJUVA® (estradiol and progesterone) capsules in Canada. BIJUVA® is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus.
    • June 2023: NGENLA from Pfizer was approved by the FDA. The product serves as a once-weekly treatment option with long-acting effects for pediatric patients with growth hormone deficiency. NGENLA was made accessible in the United States in August 2023.

    • April 2023: Novo Nordisk announced FDA approval for a new use of Sogroya. These guidelines are for children aged +2.5 years who experience growth failure due to inadequate secretion of growth hormone.

Key Findings of the Study 

    • Growing acceptance of transgender individuals’ fuels demand for gender-affirming treatments like HRT to develop desired secondary sexual characteristics.   
    • New HRT drug formulations offer precise dosing, efficacy, fewer side effects, and convenience. They are superior to traditional oral formulations.
    • New HRT options like patches, gels, and sublingual tablets improve treatment adherence and patient satisfaction for women.
    • Aging population in North America drives market for hormone replacement treatments due to hormonal imbalances and menopausal symptoms experienced by older individuals.
Pristine Intelligence LLP

Conatct Us

Would you like to get in touch? We'll be happy to talk!

Press Contact